CLINICAL TRIALS PROFILE FOR LOTENSIN HCT
✉ Email this page to a colleague
All Clinical Trials for LOTENSIN HCT
| Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
|---|---|---|---|---|---|---|
| NCT00630708 ↗ | Safety of Dual Blockage of Rennin-angiotensin System in Patients With Advanced Renal Insufficiency | Terminated | Nanfang Hospital of Southern Medical University | N/A | 2008-02-01 | The primary aim of the present study is to assess the safety of combined treatment of benazepril (an ACE inhibitor) or losartan (an ARB) in non-diabetic patients with advanced renal insufficiency. |
| NCT00649038 ↗ | Fed Study of Benazepril HCl and Hydrochlorothiazide Tablets 20 mg/25 mg to Lotensin HCT® Tablets 20 mg/25 mg | Completed | Mylan Pharmaceuticals | Phase 1 | 2002-12-01 | The objective of this study was to investigate the bioequivalence of Mylan benazepril HCl and hydrochlorothiazide 20 mg/25 mg to Novartis Lotensin HCT® 20 mg/25 mg combination tablets following a single, oral 40 mg/50 mg (2 x 20 mg/25 mg) dose administration under fed conditions. |
| NCT00649597 ↗ | Fasting Study of Benazepril HCl and Hydrochlorothiazide Tablets 20 mg/25 mg to Lotensin HCT® Tablets 20 mg/25 mg | Completed | Mylan Pharmaceuticals | Phase 1 | 2002-11-01 | The objective of this study was to investigate the bioequivalence of Mylan benazepril HCl and hydrochlorothiazide 20 mg/25 mg to Novartis Lotensin HCT® 20 mg/25 mg combination tablets following a single, oral 40 mg/50 mg (2 x 20 mg/25 mg) dose administration under fasting conditions. |
| NCT00836537 ↗ | Benazepril HCl 40 mg Tablets, Fed | Completed | Teva Pharmaceuticals USA | Phase 1 | 2001-03-01 | This study will compare the relative bioavailability (rate and extent of absorption) of 40 mg Benazepril Hydrochloride Tablets by TEVA Pharmaceuticals Industries, Ltd. with that of 40 mg LOTENSIN® Tablets by Novartis Pharmaceuticals following a single oral dose (1 x 40 mg) in healthy adult volunteers under non-fasting conditions. |
| NCT00836576 ↗ | Benazepril HCl 40 mg Tablets, Fasting | Completed | Teva Pharmaceuticals USA | Phase 1 | 2001-02-01 | The objective of this randomized, single-dose, two-way crossover evaluation is to compare the oral bioavailability of a test benazepril HCl formulation (TEVA Pharmaceutical Industries Ltd.) to an equivalent oral dose of the commercially available benazepril HCl (Lotensin®, Novartis Pharmaceuticals Corporation) in a test population of 40 adults under fasting conditions. |
| NCT00907374 ↗ | Low Dose Versus Aggressive Inhibition of the Renin-Angiotensin-Aldosterone (RAS) to Treat Microalbuminuria | Completed | Charles Drew University of Medicine and Science | N/A | 2005-07-01 | The objective of the study is to assess the effect of standard versus aggressive inhibition of the renin-angiotensin system (RAS)in type 2 diabetic patients with microalbuminuria (MA) on; a)progression of microalbuminuria, b)estimated glomerular filtration rate (eGFR), c)endothelial dysfunction (measured by post-hyperemia arterial tonometry) and d)the slowing of the progression of atherosclerotic disease (measured by carotid intima media thickness [CIMT]). |
| >Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for LOTENSIN HCT
Condition Name
Clinical Trial Locations for LOTENSIN HCT
Trials by Country
Clinical Trial Progress for LOTENSIN HCT
Clinical Trial Phase
Clinical Trial Sponsors for LOTENSIN HCT
Sponsor Name
